Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer.
Various studies have demonstrated the safety and efficacy of recombinant human thyroid-stimulating hormone (rhTSH) for radioiodine remnant ablation. On this basis, rhTSH was approved in Europe for the radioiodine ablation of low-risk differentiated thyroid cancer (DTC) during thyroid hormone therapy with L-thyroxine (L-T4). Moreover, in December 2007, the US Federal Drug Administration approved the use of rhTSH for adjuvant treatment with radioiodine in patients with DTC without evidence of metastatic thyroid cancer. Quality of life was found to be better with rhTSH preparation than with L-thyroxine withdrawal, thereby resulting in benefits for society as a whole. Furthermore, rhTSH for radioiodine remnant ablation results in a longer effective radioiodine half-life within remnant thyroid tissue and a lower specific absorbed dose in the blood and exposure of bone marrow to X-rays. More studies are required to establish the amount of radioiodine to be administered especially in high-risk patients.
Biondi
Bernadette
B
Department of Clinical and Molecular, Endocrinology and Oncology, University of Naples Federico II, Naples, Italy. bebiondi@unina.it
Pulcrano
Melania
M
Pagano
Loredana
L
Lombardi
Gaetano
G
J Clin Endocrinol Metab. 1997 Jan;82(1):11-4
8989223
J Clin Endocrinol Metab. 2000 Oct;85(10):3640-5
11061516
Thyroid. 2008 Jul;18(7):687-94
18630995
Eur J Endocrinol. 2007 May;156(5):531-8
17468188
Nucl Med Rev Cent East Eur. 2000;3(1):83-8
14600988
Thyroid. 2001 Sep;11(9):865-9
11575856
J Clin Endocrinol Metab. 2006 Mar;91(3):926-32
16384850
J Nucl Med. 2005 Jan;46 Suppl 1:28S-37S
15653649
J Clin Endocrinol Metab. 2004 Aug;89(8):3668-76
15292285
Endocr Relat Cancer. 2005 Mar;12(1):49-64
15788638
J Endocrinol Invest. 1999;22(11 Suppl):30-4
10727003
J Clin Endocrinol Metab. 1998 Dec;83(12):4195-203
9851751
Eur J Endocrinol. 2006 Sep;155(3):405-14
16914594
Thyroid. 2005 Oct;15(10):1147-55
16279848
J Clin Endocrinol Metab. 2006 Mar;91(3):878-84
16394083
J Clin Endocrinol Metab. 2007 Sep;92(9):3542-6
17609306
N Engl J Med. 1997 Sep 25;337(13):888-96
9302303
J Endocrinol Invest. 2002 Jan;25(1):44-52
11883865
Eur J Endocrinol. 2007 Jan;156(1):13-9
17218721
J Clin Endocrinol Metab. 2002 Sep;87(9):4063-8
12213846
J Clin Endocrinol Metab. 2003 Sep;88(9):4110-5
12970272
J Clin Endocrinol Metab. 2001 Apr;86(4):1447-63
11297567
Endocr Pract. 1998 Sep-Oct;4(5):282-6
15251726
Eur J Nucl Med Mol Imaging. 2004 Jun;31(6):924; author reply 924-5
15034676
J Nucl Med. 2002 Nov;43(11):1482-8
12411552
Thyroid. 2008 May;18(5):509-16
18426363
J Nucl Med. 2006 Apr;47(4):648-54
16595499
Eur J Endocrinol. 2006 Jun;154(6):787-803
16728537
Thyroid. 2006 Feb;16(2):109-42
16420177
J Nucl Med. 2004 Sep;45(9):1549-54
15347723
Am J Roentgenol Radium Ther Nucl Med. 1962 Jan;87:171-82
13867399